SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, the health technology company creating tools that empower people to prevent, diagnose, and treat their diseases, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in genomics and machine learning. The SAB will serve as strategic and scientific counsel, working closely with Freenome’s management team to advance the development of the company’s technology platform and commercial disease screening products.
“We are honored to welcome these leading experts in the fields of genomics and computational biomedicine to our newly formed Scientific Advisory Board,” said Gabe Otte, Chief Executive Officer of Freenome. “The expertise that the new SAB brings to our executive team will be invaluable in helping guide the development of our platform, as we work to bring accurate, accessible and non-invasive disease screening to doctors and their patients.”
The inaugural members include:
- Olivier Elemento, Ph.D. is Director of the Englander Institute for Precision Medicine, Head of the Cancer Systems Biology Laboratory, and Associate Professor of Computational Genomics in Computational Biomedicine at Weill Cornell Medical College. He specializes in using ultrafast genome sequencing, high-performance computing, mathematical modeling, big data and machine learning techniques to develop new ways to help prevent, diagnose, treat and ultimately cure cancer. Olivier also serves as co-Assistant Dean for Scientific Computing, Associate Director of the Institute for Computational Biomedicine, and Co-Chair of the Genetics, Epigenetics and Systems Biology Program at the Meyer Cancer Center. He is also a Walter B. Wriston Research Scholar.
- Anshul Kundaje, Ph.D. is an Assistant Professor of Genetics and Computer Science at Stanford University. His primary research area is computational regulatory genomics. He specializes in developing interpretable deep learning and other machine learning approaches for large-scale integrative analysis of functional genomic and genetic data to decipher the 1D and 3D regulatory architecture of the genome, learn predictive models of transcriptional regulation and understand the regulatory effects of natural and disease-associated genetic variation. Anshul has previously led integrative analysis efforts for the ENCODE Project and the Roadmap Epigenomics Project. Anshul is a recipient of the 2014 Alfred Sloan Fellowship and the 2016 NIH Director’s New Innovator Award.
“Freenome is pioneering a unique approach to early disease detection and intervention and I am looking forward to working closely with them as they look well beyond traditional liquid biopsy techniques to re-invent cancer screening and treatment,” said Dr. Elemento.
“I am excited to support Freenome in developing novel computational methods that measure patients’ immune responses to cancer and other diseases,” added Dr. Kundaje. “The future of personalized medicine is inevitably connected to the future of artificial intelligence, and Freenome is leading the charge.”
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors. For more information, please visit Freenome online at: www.Freenome.com.